Endothelial PANNEXIN1-induced inflammation in alzheimer's disease

Active Grant Awarded

Award ID
R03AG087474
Recipient
Awarding agency
Obligated
$357,000

Award facts

Assistance listing
93.866 Aging Research
Completion date 11% complete
Place of performance
Boston, MA 02111, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute on Aging, awarded Tufts Medical Center Parent, Inc., doing business as Tufts Medical Center, $357,000 on August 28, 2026, under the Aging Research program (CFDA 93.866) via grant R03AG087474. The project, Endothelial Pannexin1-Induced Inflammation in Alzheimer's Disease, tests whether amyloid-B upregulates cerebral endothelial pannexin1 (PANX1) expression, which would promote vascular dysfunction and Alzheimer's disease progression through increased neuroinflammation and blood-brain barrier breakdown. Aim 1 determines the mechanism by which the PANX1-purinergic signaling axis exacerbates amyloid-B-induced endothelial dysfunction. The ultimate completion date is August 31, 2028, and place of performance is Boston, MA 02111. The assistance type is a grant. The Aging Research program supports biomedical, social, and behavioral research on the aging process and on the diseases and needs of aging people, with the National Institute on Aging emphasizing prevention and treatment of Alzheimer's disease and related dementias.

Description

Abstract
Alzheimer's disease is the most prevalent form of dementia in the elderly and is associated with exacerbated neuroinflammation. A connection between neuroinflammation in alzheimer's disease and vascular dysfunction in both pre-clinical and clinical studies has been identified, but the vascular mechanisms contributing to inflammation in alzheimer's disease remain unclear. PANNEXIN1 (PANX1) channels in cerebral endothelial cells regulate the release of ATP, which subsequently activates downstream purinergic signaling cascades in the vasculature. Purinergic signaling is a critical regulator of neuroinflammation in alzheimer's disease and extracellular nucleotide activation of purinergic receptors has been found to promote alzheimer's disease pathology. We have demonstrated that PANX1 is significantly increased in cerebral endothelial cells from mouse models of alzheimer's disease, human primary brain endothelial cells exposed to increased amyloid-Β levels, and in endothelial cells from patients with alzheimer's disease. PANX1 is activated downstream of TNF⍺ resulting in leukocyte adhesion and sepsis-induced peripheral endothelial barrier breakdown. Clinical data demonstrate a positive correlation between serum levels of tnfα and cognitive decline in alzheimer's disease patients. Taken together, these data suggest that endothelial PANX1 may contribute to neuroinflammation in alzheimer's disease; however, the role of endothelial PANX1-mediated inflammation in alzheimer's disease is entirely unknown. We hypothesize that amyloid-Β upregulates cerebral endothelial PANX1 expression, which promotes vascular dysfunction and progression of alzheimer's disease via increased neuroinflammation and blood brain barrier (BBB) breakdown. We will test this novel concept in 2 aims. Aim 1 will determine the mechanism by which PANX1- purinergic signaling axis exacerbates amyloid-Β-induced endothelial inflammation in vitro utilizing primary human brain endothelial cells. Aim 2 will evaluate the role of endothelial PANX1 in driving ad-associated neuroinflammation and pathology in vivo utilizing the APP/PS1 TG mouse model of alzheimer's disease with and without inducible deletion of endothelial PANX1. Successful completion of our study will identify endothelial PANX1 as a contributor to neuroinflammation in alzheimer's disease, providing a novel target for future therapeutic intervention to reduce vascular dysfunction and improve cognitive function in alzheimer's disease patients.

Quick answers

Who received award R03AG087474?

R03AG087474 was awarded to Tufts Medical Center Parent, Inc. by National Institute on Aging (National Institutes of Health) on August 28, 2026.

How much is award R03AG087474 worth?

$357,000 has been obligated on R03AG087474.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award